This review highlights the progress achieved in transition-metal (ruthenium, rhodium, iridium, and nickel) catalyzed asymmetric hydrogenation of unsaturated sulfones including substrate scopes, catalytic mechanisms, and applications.
A highly chemo- and enantioselective hydrogenation of arylidene chromanones/cyclohexanones catalyzed by the Rh-f-spiroPhos complex has been developed, providing chiral chromanones with up to 98% ee and achieving high turnover numbers (TON = 2000).
A novel and efficient approach for obtaining allylic sulfones was demonstrated via palladium-catalyzed hydrosulfonylation of cyclopropenes.
This review emphasizes the importance of integrating structural insights of current therapeutics with pharmacological tactics to accelerate development of new therapeutics targeting RAAS for improved and efficacious cardiovascular outcomes.
Enantioselective hydrogenation of α-trifluoromethylidene lactams catalyzed by the Rh/f-spiroPhos complex is first developed, providing an efficient approach for synthesis of various chiral trifluoroethyl lactams, with up to 99.9% ee and high turnover numbers (up to 10500).